Skip Navigation



JAC Advance Access published online on May 9, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki153
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/6/954    most recent
dki153v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Landman, D.
Right arrow Articles by Quale, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Landman, D.
Right arrow Articles by Quale, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
Received December 23, 2004
Revised April 4, 2005
Accepted April 13, 2005

Original article

Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B

David Landman 1*, Simona Bratu 1, Maqsood Alam 1, and John Quale 1

1 Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 77, Brooklyn, NY 11203, USA

* To whom correspondence should be addressed.
David Landman, E-mail: dlandman{at}downstate.edu


  Abstract

Objectives: To determine the prevalence of Pseudomonas aeruginosa isolates with reduced susceptibility to polymyxin B, and to assess the in vitro activity of antibiotic combinations.

Methods: All unique patient isolates of P. aeruginosa were collected from 11 Brooklyn, NY hospitals during a three month period in 2003. Isolates with reduced susceptibility to polymyxin B (MIC > 2 mg/L) underwent ribotyping. The activity of polymyxin B combined with rifampicin, azithromycin and/or imipenem was tested by the chequerboard and time-kill methods against a subset of isolates.

Results: Of 527 isolates, only 61% were susceptible to imipenem. Twenty-five isolates (5%), from 8/11 hospitals, had reduced susceptibility to polymyxin B (MICs 4-8 mg/L), compared with 0/691 isolates collected in 2001. Ten of 25 were resistant to multiple other antibiotic classes. Ribotyping of the isolates revealed 19 unique types. Chequerboard testing of the 10 multiresistant isolates demonstrated synergy for the combinations of polymyxin B with azithromycin, imipenem and rifampicin in 6, 2, and 1 isolates, respectively. Time-kill studies revealed bactericidal activity for the following antibiotics when combined with polymyxin B: imipenem plus rifampicin against all 10 isolates, rifampicin in 9/10 isolates, imipenem in 8/10 isolates and azithromycin in 4/10 isolates. MICs of bacteria surviving incubation in polymyxin B alone rose for 4/9 isolates (MIC range 12-48 mg/L).

Conclusions: P. aeruginosa with reduced susceptibility to polymyxin B have emerged in multiple strains in Brooklyn, NY. Combinations of polymyxin B with rifampicin and/or imipenem are bactericidal. The clinical utility of these combinations remains to be determined.

Keywords: antibiotic resistance; imipenem; rifampicin; azithromycin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. Barrow and D. H. Kwon
Alterations in Two-Component Regulatory Systems of phoPQ and pmrAB Are Associated with Polymyxin B Resistance in Clinical Isolates of Pseudomonas aeruginosa
Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5150 - 5154.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
O. Cirioni, C. Silvestri, R. Ghiselli, F. Orlando, A. Riva, F. Mocchegiani, L. Chiodi, S. Castelletti, E. Gabrielli, V. Saba, et al.
Protective effects of the combination of {alpha}-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection
J. Antimicrob. Chemother., December 1, 2008; 62(6): 1332 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. Landman, C. Georgescu, D. A. Martin, and J. Quale
Polymyxins Revisited
Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. Y. Peleg, H. Seifert, and D. L. Paterson
Acinetobacter baumannii: Emergence of a Successful Pathogen
Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
T. M. Arnold, G. N. Forrest, and K. J. Messmer
Polymyxin antibiotics for gram-negative infections
Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 819 - 826.
[Abstract] [Full Text] [PDF]

Home page
 INT J LOW EXTREM WOUNDSHome page
C. Tascini, F. Menichetti, G. Gemignani, F. Palumbo, A. Leonildi, A. Tedeschi, and A. Piaggesi
Clinical and Microbiological Efficacy of Colistin Therapy in Combination With Rifampin and Imipenem in Multidrug-Resistant Pseudomonas aeruginosa Diabetic Foot Infection With Osteomyelitis
International Journal of Lower Extremity Wounds, September 1, 2006; 5(3): 213 - 216.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.